.

Pharmaceutical Business Intelligence

  • Predict branded drug patent expiration
  • Obtain formulation and manufacturing information
  • Drug patents and clinical trials in dozens of countries

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

DrugPatentWatch Database Preview

EQUETRO Drug Profile

« Back to Dashboard

Which patents cover Equetro, and what substitute generic drugs are available?

Equetro is a drug marketed by Validus Pharms Inc and is included in one NDA. There is one patent protecting this drug and two Paragraph IV challenges.

This drug has one patent family member in one country.

The generic ingredient in EQUETRO is carbamazepine. There are twenty-seven drug master file entries for this compound. Forty-five suppliers are listed for this compound. There is one tentative approval for this compound. Additional details are available on the carbamazepine profile page.

Summary for Tradename: EQUETRO

Patents:1
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Bulk Api Vendors: see list91
Clinical Trials: see list1
Patent Applications: see list5,869
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:EQUETRO at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Validus Pharms Inc
EQUETRO
carbamazepine
CAPSULE, EXTENDED RELEASE;ORAL021710-001Dec 10, 2004RXYesNo6,977,253► Subscribe ► Subscribe
Validus Pharms Inc
EQUETRO
carbamazepine
CAPSULE, EXTENDED RELEASE;ORAL021710-002Dec 10, 2004RXYesNo6,977,253► Subscribe ► Subscribe
Validus Pharms Inc
EQUETRO
carbamazepine
CAPSULE, EXTENDED RELEASE;ORAL021710-003Dec 10, 2004RXYesYes6,977,253► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: EQUETRO

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Validus Pharms Inc
EQUETRO
carbamazepine
CAPSULE, EXTENDED RELEASE;ORAL021710-001Dec 10, 20045,326,570► Subscribe
Validus Pharms Inc
EQUETRO
carbamazepine
CAPSULE, EXTENDED RELEASE;ORAL021710-003Dec 10, 20045,912,013► Subscribe
Validus Pharms Inc
EQUETRO
carbamazepine
CAPSULE, EXTENDED RELEASE;ORAL021710-001Dec 10, 20045,912,013► Subscribe
Validus Pharms Inc
EQUETRO
carbamazepine
CAPSULE, EXTENDED RELEASE;ORAL021710-003Dec 10, 20045,326,570► Subscribe
Validus Pharms Inc
EQUETRO
carbamazepine
CAPSULE, EXTENDED RELEASE;ORAL021710-002Dec 10, 20045,912,013► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: EQUETRO

Drugname Dosage Strength RLD Submissiondate
carbamazepineExtended-release Capsules100 mgEquetro5/23/2014
carbamazepineExtended-release Capsules200 mg and 300 mgEquetro8/21/2007

International Patent Family for Tradename: EQUETRO

Country Document Number Estimated Expiration
Canada2452588► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc